J&J Unit Veridex to Help Nuvera Market Its Cancer Dxs Worldwide
April 14, 2009
J&J Unit Veridex to Help Nuvera Market Its Cancer Dxs Worldwide
Terms of the deal call for Veridex to market the tests, which were developed on the Affymetrix GeneChip platform to predict response to tamoxifen and taxane-containing chemotherapy in breast cancer. The deal is open to other tests in as-yet unknown indications.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- At Investor Confab, Illumina Details 'Enormous' DTC Demand as Market Shifts to Less Complex Chips
May 21, 2013 / BioArray News - ICCG, Awaiting Funding, Moves Ahead with Plans to Build Database of Genomic, Phenotypic Information
May 21, 2013 / BioArray News - Q&A: INMEGEN's Alfredo Hidalgo on Using Genomics to Address Mexico's Most Pressing Health Problems
May 21, 2013 / BioArray News - SQI's Q2 Revenues Drop to Zero
May 21, 2013 / GenomeWeb Daily News - NanoString Technologies Files to Go Public
May 20, 2013 / GenomeWeb Daily News